Autonomix Medical (AMIX) Company Overview

THE WOODLANDS, TX, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the  Company's website . For the segment, Brad Hauser, CEO of Autonomix, shared feedback from the recently held 43rd Annual J.P. Morgan Healthcare Conference and recapped some of the latest relevant industry news.

Design lock for ASIC microchip follows successful completion of in vivo preclinical and extensive bench testing Manufacturing of ASIC microchip for targeted use in humans has been initiated Company advancing toward submitting Investigational Device Exemption (“IDE”), and if approved, will commence a pivotal clinical trial to support a De Novo application for FDA approval THE WOODLANDS, TX, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has finalized the design, achieving “design lock”, for its Application Specific Integrated Circuits (ASIC) microchip following the successful completion of in vivo preclinical testing and extensive bench testing, continuing progress toward its U.S. pivotal trial. “This design lock represents a significant milestone in the advancement of our innovative technology, placing us another step closer to commencing a pivotal clinical trial in the United States, planned in 2025.

Live video webcast on Wednesday, January 22 nd at 4:00 PM ET THE WOODLANDS, TX, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, January 22, 2025 at 4:00 PM ET. As part of the event, Brad Hauser, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook.

Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass THE WOODLANDS, TX, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. patent 12,064,256 (‘256 patent) titled, Systems and Methods for Treating Cancer and/or Augmenting Organ Function. The issued ‘256 patent covers technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain.

THE WOODLANDS, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the  Company's website . For the CEO Corner segment, Brad Hauser, CEO of Autonomix, reflected on the Company's progress made over the last year and shared insight into the year ahead.

First-in-class catheter-based sensing technology designed to sense neuronal signals that indicate pain or disease and destroy those nerves at the source

THE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previously announced underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $10.0 million, prior to deducting underwriting discounts and commissions and offering expenses, which amount includes the partial exercise of the over-allotment option granted to the underwriter.

THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses.

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure